Biotech
Friday, November 3rd, 2023 2:22 pm EDT
Key Points
- Novo Nordisk has reported that 80% of U.S. patients with insurance coverage who use its weight loss treatment Wegovy are paying less than $25 per month for the drug, despite its high list price of around $1,350. This suggests that many insured Americans have access to the drug without bearing the full cost.
- While some U.S. health insurers have hesitated to cover Wegovy and similar obesity drugs due to their high monthly expenses, most major health plans and pharmacy benefit managers are now covering Wegovy. The company is working to secure employer coverage and stronger access for Americans.
- Novo Nordisk hopes that new data demonstrating Wegovy’s heart health benefits, reducing the risk of cardiovascular events by 20%, will encourage more insurers to provide coverage. Approximately 50 million Americans with obesity could be eligible for Wegovy coverage under their health plans, as the demand for obesity treatments continues to grow.
Novo Nordisk has reported that 80% of U.S. patients with insurance coverage who use its weight loss treatment Wegovy are paying less than $25 per month for the drug, despite its list price of around $1,350. This suggests that many insured Americans have access to the drug without bearing the full cost. While some U.S. health insurers have hesitated to cover Wegovy and similar obesity drugs due to their high monthly expenses, Novo Nordisk is hoping that new data demonstrating the drug’s heart health benefits, reducing the risk of cardiovascular events by 20%, will encourage more insurers to provide coverage. About 50 million Americans with obesity could be eligible for Wegovy coverage under their health plans.
For the full original article on CNBC, please click here: https://www.cnbc.com/2023/11/02/wegovy-insured-patients-25-dollars-month.html
